Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist... Read More

JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal government. Of the two technologies associated with Traumatic Brain Injuries (TBI)/Suicide Ideation for which we chose to pursue government funding, Athena’s success via the... Read More

JACKSON CENTER, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here . Based on the encouraging results... Read More

JACKSON CENTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wrist monitor and used a mobile... Read More

JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology and Athena... Read More

JACKSON CENTER, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week’s Press release, Part A . This Part B supplements that release of a few days ago. As always reach out to us if you have any... Read More

JACKSON CENTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) To our shareholders: As promised, this is the second of three Press Releases on our recent progress. If you have not had a chance to review that last one , on the good news on our Tri-aX™ Nasal Spray for TBI, please do. This one follows the same process. This Press Release is focused on LDN+, as related to Post Traumatic Stress Disorder... Read More

JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to it shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-ax TM TBI Nasal Spray Treatment - the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we... Read More

JACKSON CENTER, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II... Read More

Walt Disney once said, "All our dreams can come true if we have the courage to pursue them". JACKSON CENTER, PA / ACCESSWIRE / May 22, 2024 / Halberd Corporation (OTC PINK:HALB) in cooperation with Athena GTX, Inc is standing at the threshold of some major advancements to treat the issues facing not only our military but people around the world. In essence, the traumas of depression, anxiety, substance use disorders, and... Read More

Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. JACKSON CENTER, PA / ACCESSWIRE / May 9, 2024 / Halberd Corporation's (OTC PINK:HALB) two active programs for the treatment and mitigation of the negative effects of traumatic brain injury (TBI) align well with the newly passed bill in the U. S. House of Representatives. Advocated by Mark... Read More

LDN+ Drug Designed to Combat PTSD and Suicidal Ideation JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants,... Read More

JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just executed Cooperative Research and Development... Read More

JACKSON CENTER, PA / ACCESSWIRE / February 8, 2024 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed last year with... Read More

JACKSON CENTER, PA / ACCESSWIRE / February 6, 2024 / Halberd Corporation's (OTC PINK:HALB) and Athena GTX's executives interviewed on "The Street Reports," discuss the relationship between Halberd and Athena and why that relationship is going to advance Halberd's breakthrough technologies toward government contracts. Listen here To get the latest on Halberd's exciting developments, subscribe by submitting this form . (... Read More

JACKSON CENTER, PA / ACCESSWIRE / January 11, 2024 / Halberd Corporation (OTC PINK:HALB) made significant advances in its technology development and accomplished major business goals during the second half of 2023. 2023 ACHIEVEMENTS Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary laser eradication methodology. Testing at Youngstown... Read More

Athena will employ its successful history of securing government contracts, spearheading such initiatives JACKSON CENTER, PA / ACCESSWIRE / January 10, 2024 / Halberd Corporation (OTC-PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, ( www.athenagtx.com ). Athena GTX is a private enterprise specializing in providing medical care solutions... Read More

Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to move Halberd forward JACKSON CENTER, PA / ACCESSWIRE / December 13, 2023 / Halberd Corporation (OTC PINK:HALB) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd's patented low dose naltrexone... Read More

MSU Research for Halberd to Transcend the TBI Nasal Spray JACKSON CENTER, PA / ACCESSWIRE / November 15, 2023 / Halberd Corporation (OTC PINK:HALB) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent TBI Nasal Spray project, as well as... Read More

JACKSON CENTER, PA / ACCESSWIRE / October 10, 2023 / Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr Mitchell S. Felder were recently interviewed on "The Street Reports Podcast" to update the public on several of the company's important projects: The significant results to-date of Halberd's proprietary nasal spray testing at Mississippi State University to... Read More

JACKSON CENTER, PA / ACCESSWIRE / October 4, 2023 / Halberd Corporation's (OTC PINK:HALB) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing: 25% reduction in Neuron Specific Enolase and 52.3% reduction in the levels of... Read More

JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI). The initial focus will be on accelerating and fine-tuning Halberd's proprietary nasal spray for suppressing the effects of... Read More

Anecdotal Results of Halberd's Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers JACKSON CENTER, PA / ACCESSWIRE / September 6, 2023 / Halberd Corporation's (OTC PINK:HALB) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of... Read More

Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product JACKSON CENTER, PA / ACCESSWIRE / August 22, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's... Read More

Scientific Paper Presented at Research Symposium JACKSON CENTER, PA / ACCESSWIRE / August 14, 2023 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigation research on Halberd's patent-pending nasal spray continues at Mississippi State University (MSU). MSU students, Jourdan, L.K., Broadaway, S. Cassen, et. al. authored and presented a paper on this project at the recent Mississippi State University... Read More

JACKSON CENTER, PA / ACCESSWIRE / July 20, 2023 / Halberd Corporation (OTC PINK:HALB). During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology products and safe, yet effective treatments for previously considered incurable or difficult-to-treat diseases. 2 nd QUARTER 2023 ACHIEVEMENTS Mississippi State University (MSU) is well on their way in testing Halberd's... Read More

JACKSON CENTER, PA / ACCESSWIRE / May 31, 2023 / Halberd Corporation (OTC PINK:HALB) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts. Mississippi State University (MSU) has completed the impacts and sample collection for Phase I of the ongoing preclinical model testing. Based on the analysis of... Read More

MSU is ahead of schedule and continues testing program JACKSON CENTER, PA / ACCESSWIRE / May 23, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd's groundbreaking patent-pending nasal spray. The nasal spray is designed to eliminate the otherwise inevitable... Read More

Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month's End JACKSON CENTER, PA / ACCESSWIRE / May 9, 2023 / Halberd Corporation (OTC PINK:HALB) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering will begin as early as next week. Medical... Read More

Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process JACKSON CENTER, PA / ACCESSWIRE / May 2, 2023 / Halberd Corporation (OTC PINK:HALB) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of this study by... Read More

JACKSON CENTER, PA / ACCESSWIRE / April 25, 2023 / Halberd Corporation (OTC PINK:HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1 st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd's laser eradication... Read More

JACKSON CENTER, PA / ACCESSWIRE / April 20, 2023 / Halberd Corporation's (OTC PINK:HALB) President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm. Gregg Sturrus were interviewed on "The Street Reports" to discuss the company's latest research discoveries and progress on eradicating CDC (Centers for Disease Control and... Read More

JACKSON CENTER, PA / ACCESSWIRE / April 17, 2023 / Halberd Corporation's (OTC PINK:HALB) successful patent protected research being conducted at Youngstown State University (YSU) on antibiotic resistant bacteria and deadly Candida auris was recently featured in a news segment on Youngstown, OH CBS News affiliate television station, WKBN . Professors and student scholar lab assistants are conducting this intricate research on... Read More

JACKSON CENTER, PA / ACCESSWIRE / April 11, 2023 / Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI). This innovative research involves the development of test mechanisms by MSU's staff to quantify and correlate the level of... Read More

JACKSON CENTER, PA / ACCESSWIRE / April 3, 2023 / Halberd Corporation (OTC PINK:HALB) on March 29 th met with five representatives from the Centers for Disease Control and Prevention (CDC). The CDC discussed Halberd's incredible success eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and deadly Candida auris samples previously provided by the CDC. Halberd participants presented the repeated success... Read More

JACKSON CENTER, PA / ACCESSWIRE / March 30, 2023 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU. The testing will focus on Halberd's patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining head trauma. The work will be... Read More

JACKSON CENTER, PA / ACCESSWIRE / March 21, 2023 / Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC. Using Halberd's patented extracorporeal (outside the body) process and patent-pending laser... Read More

Halberd's patented process demonstrates eradication of multiple strains of antibiotic resistant bacteria and fungi in under 10 minutes. JACKSON CENTER, PA / ACCESSWIRE / March 14, 2023 / Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd's incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and Candida... Read More

Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in vitro JACKSON CENTER, PA / ACCESSWIRE / February 21, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under 10 minutes. Halberd's patented extracorporeal process and patent-pending laser eradication method in conjunction... Read More

Halberd Demonstrates Eradication of Candida Auris Fungus in as little as 5 minutes. JACKSON CENTER, PA / ACCESSWIRE / February 13, 2023 / Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC... Read More

Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing JACKSON CENTER, PA / ACCESSWIRE / February 8, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia... Read More

Tests to be scheduled at Mississippi State University JACKSON CENTER, PA / ACCESSWIRE / January 31, 2023 / Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several... Read More

College of Veterinary Medicine to conduct testing JACKSON CENTER, PA / ACCESSWIRE / January 24, 2023 / Halberd Corporation's (OTC PINK:HALB) has agreed to conduct animal testing at Mississippi State University's (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working... Read More

Profound Advancements Explained JACKSON CENTER, PA / ACCESSWIRE / January 3, 2023 / Halberd Corporation (OTC PINK:HALB) The second half of 2022 was a very busy time. 2022 2 nd HALF ACHIEVEMENTS Halberd's previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%. Halberd formed a Cancer Therapeutics... Read More

Halberd's method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains. JACKSON CENTER, PA / ACCESSWIRE / December 6, 2022 / Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication technology which successfully eradicated... Read More

CEO William Hartman and CTO Mitchell Felder report successful application of Halberd's patented methodology for Cancer Antigen Eradication Treatment. JACKSON CENTER, PA / ACCESSWIRE / December 5, 2022 / Halberd Corporation's (OTC-PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments,... Read More

Reason for correction - to correct percentages from rounded figures to more accurate actual numbers. Boosts effectiveness by 44.4% of commercially available Covid antibody in cocktail JACKSON CENTER, PA / ACCESSWIRE / December 1, 2022 / Halberd Corporation's (OTC-PINK:HALB) Covid research has led to a scientific article titled, " A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail... Read More

Boosts effectiveness by 50% of commercially available Covid antibody in cocktail JACKSON CENTER, PA / ACCESSWIRE / November 30, 2022 / Halberd Corporation's (OTC PINK:HALB) Covid research has led to a scientific article titled, " A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article has been peer reviewed and accepted for... Read More